Biota records small year-end loss
27 August, 2008 by Dylan Bushell-EmblingBiota’s long-running legal battle with GSK has taken its toll, with the company recording a $20 million loss for the year.
Horses for courses for Bioeffectives
27 August, 2008 by Dylan Bushell-EmblingBioeffectives show promise as effective treatment of equine gastric ulcers and as a replacement for antibiotics in poultry feed.
No pain for Xenome
21 August, 2008 by Dylan Bushell-EmblingSynthetic venom peptide shows promise in trials
Spine fusion for Mesoblast
21 August, 2008 by Dylan Bushell-EmblingMesoblast's stem cells effective method for cervical spine fusion
Market in sight for Pharmaxis
20 August, 2008 by Dylan Bushell-EmblingPharmaxis concludes Phase 3 trial of Bronchitol
Happy as a pig
20 August, 2008 by Dylan Bushell-EmblingImugene reports early PRRS vaccine trial results
Anadis fights flu
20 August, 2008 by Dylan Bushell-EmblingAnadis shows proof-of-principle for spray-based 'flu fighter'
Aldridge quits Peplin
19 August, 2008 by Dylan Bushell-EmblingPeplin appoints new CEO and president/CMO
$3 million for Chagas research
15 August, 2008 by Kate McDonaldMurdoch University and Epichem get $3 million Chagas research boost
Genentech rejects Roche bid
15 August, 2008 by Kate McDonaldUS biotech Genentech rejects $43.7 billion takeover deal
Acrux-Organon partnership dropped
15 August, 2008 by Dylan Bushell-EmblingSchering-Plough cancels two projects with Acrux
Life's Full Court appeal accepted
15 August, 2008 by Dylan Bushell-EmblingLife's legal battle with Bell IXL will continue, after the Full Court ordered a retrial.
Acrux heads to the Finnish
14 August, 2008 by Dylan Bushell-EmblingAcrux signs exclusive manufacturing partner for Testosterone MD-Lotion
Circadian owns Vegenics
14 August, 2008 by Dylan Bushell-EmblingCircadian finalises Vegenics purchase
